Literature DB >> 22126248

Epigenomics of leukemia: from mechanisms to therapeutic applications.

Cristina Florean1, Michael Schnekenburger, Cindy Grandjenette, Mario Dicato, Marc Diederich.   

Abstract

Leukemogenesis is a multistep process in which successive transformational events enhance the ability of a clonal population arising from hematopoietic progenitor cells to proliferate, differentiate and survive. Clinically and pathologically, leukemia is subdivided into four main categories: chronic lymphocytic leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and acute myeloid leukemia. Leukemia has been previously considered only as a genetic disease. However, in recent years, significant advances have been made in the elucidation of the leukemogenesis-associated processes. Thus, we have come to understand that epigenetic alterations including DNA methylation, histone modifications and miRNA are involved in the permanent changes of gene expression controlling the leukemia phenotype. In this article, we will focus on the epigenetic defects associated with leukemia and their implications as biomarkers for diagnostic, prognostic and therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22126248     DOI: 10.2217/epi.11.73

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  41 in total

1.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.

Authors:  Tino Schenk; Weihsu Claire Chen; Stefanie Göllner; Louise Howell; Liqing Jin; Katja Hebestreit; Hans-Ulrich Klein; Andreea C Popescu; Alan Burnett; Ken Mills; Robert A Casero; Laurence Marton; Patrick Woster; Mark D Minden; Martin Dugas; Jean C Y Wang; John E Dick; Carsten Müller-Tidow; Kevin Petrie; Arthur Zelent
Journal:  Nat Med       Date:  2012-03-11       Impact factor: 53.440

2.  Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.

Authors:  Christopher B Benton; Deborah A Thomas; Hui Yang; Farhad Ravandi; Michael Rytting; Susan O'Brien; Anna R Franklin; Gautam Borthakur; Samuel Dara; Monica Kwari; Sherry R Pierce; Elias Jabbour; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Br J Haematol       Date:  2014-07-26       Impact factor: 6.998

Review 3.  γ-H2AX and other histone post-translational modifications in the clinic.

Authors:  Christophe E Redon; Urbain Weyemi; Palak R Parekh; Dejun Huang; Allison S Burrell; William M Bonner
Journal:  Biochim Biophys Acta       Date:  2012-03-09

4.  DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia.

Authors:  Christopher C Oakes; Marc Seifert; Yassen Assenov; Lei Gu; Martina Przekopowitz; Amy S Ruppert; Qi Wang; Charles D Imbusch; Andrius Serva; Sandra D Koser; David Brocks; Daniel B Lipka; Olga Bogatyrova; Dieter Weichenhan; Benedikt Brors; Laura Rassenti; Thomas J Kipps; Daniel Mertens; Marc Zapatka; Peter Lichter; Hartmut Döhner; Ralf Küppers; Thorsten Zenz; Stephan Stilgenbauer; John C Byrd; Christoph Plass
Journal:  Nat Genet       Date:  2016-01-18       Impact factor: 38.330

Review 5.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

6.  Biology of CML stem cells: the basis for clinical heterogeneity?

Authors:  J M Goldman; M Gordon; A Bazeos; D Marin
Journal:  Leuk Suppl       Date:  2012-08-09

Review 7.  Epigenetic roots of immunologic disease and new methods for examining chromatin regulatory pathways.

Authors:  Ian A MacDonald; Nathaniel A Hathaway
Journal:  Immunol Cell Biol       Date:  2014-12-23       Impact factor: 5.126

8.  Harmine, a Novel DNA Methyltransferase 1 Inhibitor in the Leukemia Cell Line.

Authors:  Arezoo Oodi; Hamed Norouzi; Naser Amirizadeh; Mahin Nikougoftar; Zahra Vafaie
Journal:  Indian J Hematol Blood Transfus       Date:  2017-01-17       Impact factor: 0.900

Review 9.  Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.

Authors:  Richat Abbas; Poe-Hirr Hsyu
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

10.  Epigenetically induced changes in nuclear textural patterns and gelatinase expression in human fibrosarcoma cells.

Authors:  M Poplineau; C Doliwa; M Schnekenburger; F Antonicelli; M Diederich; A Trussardi-Régnier; J Dufer
Journal:  Cell Prolif       Date:  2013-04       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.